FDA
-
-
-
-
-
-
-
Xenetic Biosciences, Inc. Reports First Quarter 2020 Financial Results and Provides Corporate Update
-
-
-
-
-
-
-
Xenetic Biosciences Receives $3 Million Milestone Payment from Shire plc for PSA-Recombinant SHP656 in Development for Long-Acting Treatment for Hemophilia
-
-
-
312,667 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

